TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
A Phase Ib Study of TQ05105 Tablets for the Treatment of Intermediate and High Risk Myelofibrosis Refractory/Relapsed/Intolerant to Ruxolitinib
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Other terminated trials from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Extensive Stage Small Cell Lung Cancer · Apr 2026
- Myelofibrosis · Phase PHASE1/PHASE2 · Dec 2025
- Advanced Endometrial Cancer · Phase PHASE2 · Nov 2025
- Breast Cancer · Phase PHASE1/PHASE2 · Nov 2025
- Advanced Hepatocellular Carcinoma · Phase PHASE1 · Nov 2025
More terminations from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Other Myelofibrosis trials with similar outcome
A PHASE1 clinical study on Myelofibrosis, this trial is terminated or withdrawn. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .